Last reviewed · How we verify
Live attenuated Japanese encephalitis virus
Live attenuated Japanese encephalitis virus is a Biologic drug developed by Sanofi. It is currently in Phase 2 development. Also known as: ChimeriVax™-JE.
At a glance
| Generic name | Live attenuated Japanese encephalitis virus |
|---|---|
| Also known as | ChimeriVax™-JE |
| Sponsor | Sanofi |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects. (PHASE1)
- Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province (PHASE4)
- Postmarketing Surveillance Study for IMOJEV® in Republic of Korea
- Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects (PHASE3)
- Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea (PHASE3)
- Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine (PHASE4)
- Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine (PHASE3)
- Post-licensure Safety Study of IMOJEV® in Thailand (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Live attenuated Japanese encephalitis virus CI brief — competitive landscape report
- Live attenuated Japanese encephalitis virus updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Live attenuated Japanese encephalitis virus
What is Live attenuated Japanese encephalitis virus?
Live attenuated Japanese encephalitis virus is a Biologic drug developed by Sanofi.
Who makes Live attenuated Japanese encephalitis virus?
Live attenuated Japanese encephalitis virus is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).
Is Live attenuated Japanese encephalitis virus also known as anything else?
Live attenuated Japanese encephalitis virus is also known as ChimeriVax™-JE.
What development phase is Live attenuated Japanese encephalitis virus in?
Live attenuated Japanese encephalitis virus is in Phase 2.
Related
- Manufacturer: Sanofi — full pipeline
- Also known as: ChimeriVax™-JE